Cardiac T2* MRI assessment in patients with thalassaemia major and its effect on the preference of chelation therapy

International Journal of Hematology

Volumn 99, Issue 6, 2014, Pages 706-713

  Akcay, Arzu ^a   Salcioglu, Zafer ^a   Oztarhan, Kazim ^a   Tugcu, Deniz ^a   Aydogan, Gonul ^a   Ayaz, Nuray Aktay ^a   Bornaun, Helen ^a   Sen, Hulya Sayilan ^a   Akici, Ferhan ^a   Akdana, Burhan ^b  

^a Istanbul Kanuni Sultan Suleyman Education and Research Hospital   (Turkey)

^b SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Cardiac iron concentration; Chelation therapy; T2* MRI; Thalassaemia major

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE MESYLATE; FERRITIN; IRON; IRON CHELATING AGENT;

ADOLESCENT; AGE; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CHELATION THERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOPPLER ECHO; DOPPLER ECHOCARDIOGRAPHY; DRUG ACCUMULATION; DRUG TISSUE LEVEL; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; LOW RISK POPULATION; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE SCANNER; SIDEROSIS; SINGLE DRUG DOSE; SPLENECTOMY; THALASSEMIA MAJOR; ADULT; ADVERSE EFFECTS; BETA-THALASSEMIA; BLOOD; BLOOD TRANSFUSION; COMPLICATION; ECHOCARDIOGRAPHY; HEART; HEART MUSCLE; HEART STROKE VOLUME; IRON OVERLOAD; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHILD; ECHOCARDIOGRAPHY; FEMALE; FERRITINS; HEART; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIUM; SPLENECTOMY; STROKE VOLUME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84905391829     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-014-1575-1     Document Type: Article

References (31)

1. Aydinok Y. Thalassemia. Hematology. 2012;17(1):S28-31.
2. Borgna-Pignatti C, Rugolotto S, De Stafano P, et al. Survival and complications in patients with transfusion and deferoxamine. Haematologica. 2004;89:1187-93. (Pubitemid 39390442)
3. Tanner MA, Galanello R, Dessi C, et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson. 2006;8:543-7.
4. Kirk P, Raughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120:1961-8.
5. Pennel DJ. T2* magnetic resonance and myocardial iron in thalassemia. Ann NY Acad Sci. 2005;1054:373-8.
6. Anderson LJ, Holden S, Davies B, et al. Cardiovascular T-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171-9. (Pubitemid 33139463)
7. Tanner MA, Porter JB, Westwood MA, et al. Myocardial T2* in patients with cardiac failure secondary to iron overload. Blood. 2005;106:406.
8. Westwood M, Anderson LJ, Firmin DN, et al. A single breathhold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging. 2003;18(1):33-9. (Pubitemid 36791266)
9. Wood JC. Impact of iron assessment by MRI. Hematol Am Soc Hematol Educ Program. 2011;2011:443-50.
10. Carpenter JP, He T, Kirk P, et al. On T2* magnetic resonance and cardiac iron. Circulation. 2011;123(14):1519-28.
11. Consensus view on choice or iron chelation therapy in transfusional iron overload for inherited anemias. http://www.emscg.nhs.uk/Library/ NUHGuidelinesforironchelationtherapy.pdf. Accessed 3 May 2012.
12. Modell B, Khan M, Darlison M, et al. Survival in beta-thalassemia major in the UK: data from the UK Thalassemia Register. Lancet. 2000;355:2051-2. (Pubitemid 30339248)
13. Borgna-Pignatti C, Cappellini MD, De Stafano P, et al. Survival and complications in thalassemia. Ann NY Acad Sci. 2005;1054:40-7. (Pubitemid 43031009)
14. Modell B, Khan M, Darlison M, et al. Improved survival of thalassemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;25:10-42.
15. Pepe A, Meloni A, Capra M, et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica. 2011;96(1):41-7.
16. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738-44.
17. Pennell DJ, Porter JB, Capellini DM, et al. Efficacy and safety of Deferasirox (Exjade®) in reducing kardiyac iron in patients with beta-thalassemia major: results from the cardiac substudy of the EPIC trial. Blood. 2008;112:3873.
18. Aydinok Y, Levent E, Bayraktaroǧlu S, et al. Talasemi major olgularinda kardiyak demir birikiminin başlangiç yaşi, kardiyak fonksiyonlar, karaciǧer demir yoǧunluǧu ve serum ferritin düzeyleri ile ilişkisi. Ulusal Pediatrik Hematoloji Kongresi, 2009.
19. Wood JC, Origa R, Agus A, et al. Onset of cardiac iron loading in pediatric patients with thalassemia major. Haematologica. 2008;93:917-20. (Pubitemid 351821730)
20. Kwiatkowski JL. Real-world use iron chelators. Hematol Am Soc Hematol Educ Program. 2011;2011:451-8.
21. Wood JC, Tyszka JM, Carson S, et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103(5):1934-6. (Pubitemid 38268994)
22. Aydinok Y, Bayraktaroglu S, Yildiz D, et al. Myocardial iron loading in patients with thalassemia major in Turkey and the potential role of splenectomy in myocardial siderosis. J Pediatr Hematol Oncol. 2011;33:374-8.
23. Thalassemia International Federation 2008. http://www.thalassaemia.org. cy/pdf/Guidelines-2nd-revised-edition-EN.pdf. Accessed 15 Nov 2011.
24. Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica. 2008;93:741-52. (Pubitemid 351669315)
25. Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators. Hemoglobin. 2006;30:239-49. (Pubitemid 43977326)
26. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood. 2010;115:2364-71.
27. Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica. 2011;96:48-54.
28. Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica. 2012;97:842-8.
29. Wood JC, Thompson AA, Paley C, et al. Deferasirox (Exjade®) monotherapy significantly reduces cardiac iron burden in chronically transfused beta-thalassemia patients: an MRI T2* study. Blood. 2008;112:3882.
30. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115:1876-84. (Pubitemid 46598901)
31. Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood. 2012;120(18):3657-69.